Levemir, a life-saving insulin drug, is being discontinued by Novo Nordisk at the end of December 2026. This decision leaves countless diabetes patients, like myself, in a precarious situation, relying on alternative options that fail to provide the same level of efficacy and safety.

Having navigated the challenges of Type 1 diabetes for nearly 30 years, I have found Levemir to be an essential part of my treatment regimen. What sets Levemir apart from other long-acting insulins like Lantus and Tresiba is its unique flexibility and safety profile. With a distinctive dosing adjustment capability, it allows for more personalized management of blood glucose levels, significantly reducing the risk of severe hypoglycemia episodes.

For many patients, the discontinuation of Levemir could have dire consequences. After experiencing several severe hypoglycemia episodes on Tresiba and Lantus, I can personally attest to the pivotal role Levemir plays in stabilizing my condition and ensuring my well-being.

Statistics indicate that approximately 422 million people worldwide suffer from diabetes (World Health Organization). A significant number of these individuals depend on insulins like Levemir to maintain their health and quality of life. Removing such a vital option could increase health risks and potentially overload healthcare systems with new cases of severe hypoglycemia and poorly managed diabetes.

This petition aims to compel Novo Nordisk to reconsider this critical decision. The lives and health of those dependent on Levemir should not be jeopardized. Novo Nordisk has been at the forefront of diabetes care, and we believe in their commitment to prioritizing patient safety and health above other considerations.

Join me in urging Novo Nordisk to continue the production of Levemir and support the countless individuals who rely on it for their well-being. Sign this petition today to help us protect the availability of life-saving diabetes treatment and advocate for safer diabetes care for everyone.